Osvaldo Brusco, MD
Endocrinology, Diabetes & Metabolism · Corpus Christi, TXNPI 1154329332
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $293,361 of the $360,095 with a category attached, or 81.5%. 40 manufacturers reported payments, led by Novo Nordisk at 44.4% of the total. Reporting peaked in 2019 at $149,462 and has fallen 86.3% since, to $20,424 in 2025. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 760 payments — averaging $473.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$160K
- Lilly USA, LLC$69K
- Sanofi-aventis U.S. LLC$47K
- Johnson & Johnson$33K
- Boehringer Ingelheim$25K
- Bayer$14K
- plus $12K from 34 others
Across 922 payments — averaging $2614.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$911K
- AbbVie$549K
- Bayer$527K
- Novo Nordisk AS$204K
- Sanofi US Services Inc.$108K
- Amgen$60K
- plus $51K from 2 others
What the payments were for
- Consulting fees$11,0653%
- Speaking & faculty fees$293,36181%
- Travel & lodging$41,80012%
- Food & beverage$13,5014%
- Education$3530%
- Entertainment$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 268 | $159,708 |
| Lilly USA, LLC | 121 | $69,147 |
| Sanofi-aventis U.S. LLC | 74 | $46,799 |
| Johnson & Johnson | 38 | $32,708 |
| Boehringer Ingelheim | 52 | $25,092 |
| Bayer | 34 | $14,238 |
| Esperion Therapeutics, Inc. | 12 | $8,430 |
| Amgen(2 entities) | 23 | $655 |
| AstraZeneca(2 entities) | 17 | $390 |
| Corcept Therapeutics | 11 | $326 |
| Radius Health, Inc. | 15 | $299 |
| Abbott | 10 | $272 |
| Dexcom, Inc. | 11 | $230 |
| Novartis | 9 | $206 |
| Medtronic(3 entities) | 6 | $166 |
| Antares Pharma, Inc. | 6 | $160 |
| Kyowa Kirin, Inc. | 2 | $156 |
| Medicure Pharma Inc. | 1 | $129 |
| Mannkind Corporation | 5 | $122 |
| Insulet Corporation | 6 | $119 |
| Xeris Pharmaceuticals, Inc. | 4 | $76 |
| Amarin Pharma, Inc. | 4 | $73 |
| Merck | 5 | $73 |
| Tolmar, Inc. | 3 | $65 |
| Kowa Pharmaceuticals America, Inc. | 3 | $64 |
| IBSA Pharma Inc. | 3 | $58 |
| Ascensia Diabetes Care US Inc. | 3 | $51 |
| Ascendis Pharma Endocrinology Inc | 1 | $43 |
| Madrigal Pharmaceuticals | 1 | $31 |
| Nevro Corp. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Cequr Corporation | 2 | $20 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| AbbVie | 1 | $18 |
| Vivus LLC | 1 | $18 |
| Lifescan, Inc. | 1 | $15 |
| Sequel Med Tech, LLC | 1 | $15 |
| Optos, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$77,508
- JARDIANCE$56,386
- RYBELSUS$52,941
- TRULICITY$35,224
- INVOKANA$32,190
- SOLIQUA 100/33$26,682
- TOUJEO$22,137
- Tresiba$16,242
- Kerendia$13,900
- NEXLIZET$8,335
- NEXLETOL$8,335
- Victoza$4,999
- Xultophy 100/3.6$2,328
- CRYSVITA$135
- HMG-CoA reductase inhibitor.$129
- FARXIGA$125
- TEPEZZA$122
- EVENITY$118
- Korlym$112
- FreeStyle Libre 2$109
How this compares
$360,095 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 543 | $738,162 |
| JardianceEmpagliflozin | 348 | $454,384 |
| MounjaroTirzepatide | 287 | $393,204 |
| TrulicityDulaglutide | 98 | $133,409 |
| Tresiba Flextouch U-200Insulin Degludec | 91 | $125,266 |
| FarxigaDapagliflozin Propanediol | 127 | $123,086 |
| JanuviaSitagliptin Phosphate | 86 | $90,363 |
| KerendiaFinerenone | 63 | $87,643 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $87,604 |
| RybelsusSemaglutide | 39 | $70,280 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $47,561 |
| TymlosAbaloparatide | 15 | $44,582 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 40 | $42,361 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $34,768 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $34,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $159,708 | $811,886600 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $69,147 | $539,329440 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $25,092 | $508,816391 claims |
| AstraZenecaFarxiga | $390 | $123,086127 claims |
| MerckJanuvia | $73 | $90,36386 claims |
| BayerKerendia | $14,238 | $87,64363 claims |
| Radius Health, Inc.Tymlos | $299 | $44,58215 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $46,799 | $42,36140 claims |
| AmgenProlia | $655 | $22,46813 claims |
| Johnson & JohnsonInvokana | $32,708 | $15,43315 claims |
| AbbVieSynthroid | $18 | $7,18077 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $6,421580 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Corpus Christi
- Brandi AddisonCorpus Christi$647K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.